We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+32.04%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.4B
AUM Growth
+$1.66B
Cap. Flow
+$453M
Cap. Flow %
7.07%
Top 10 Hldgs %
53.23%
Holding
81
New
14
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$98.5M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$88.5M
3
CRGX
CARGO Therapeutics
CRGX
+$87.8M
4
ALKS icon
Alkermes
ALKS
+$78.3M
5
ARGX icon
argenx
ARGX
+$74.6M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$116M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$28.5M
3
ILMN icon
Illumina
ILMN
+$25.8M
4
AXNX
Axonics, Inc. Common Stock
AXNX
+$24.8M
5
SCPH
scPharmaceuticals
SCPH
+$23.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
26
DELISTED
Merus
MRUS
$65.3M 1.02%
2,373,625
+376,861
+19% +$8.8M
ESTA icon
27
Establishment Labs
ESTA
$2.28B
$64.6M 1.01%
2,494,138
– –
TARS icon
28
Tarsus Pharmaceuticals
TARS
$2.84B
$63.8M 1%
3,152,341
+271,640
+9% +$4.54M
ETNB
29
DELISTED
89bio
ETNB
$62.3M 0.97%
+5,578,931
New +$51.3M
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$60.5M 0.95%
6,689,789
– –
APGE icon
31
Apogee Therapeutics
APGE
$10.2B
$59.9M 0.94%
2,142,591
– –
INSM icon
32
Insmed
INSM
$28.6B
$57.8M 0.9%
1,865,108
– –
OBIO icon
33
Orchestra BioMed
OBIO
$254M
$51.3M 0.8%
5,620,640
– –
SYRE icon
34
Spyre Therapeutics
SYRE
$9.25B
$48M 0.75%
+2,232,760
New +$30.8M
FULC icon
35
Fulcrum Therapeutics
FULC
$297M
$36.9M 0.58%
5,469,956
-348,848
-6% -$1.55M
TSHA icon
36
Taysha Gene Therapies
TSHA
$1.89B
$29.9M 0.47%
16,893,185
– –
DHR icon
37
Danaher
DHR
$144B
$27.4M 0.43%
+118,584
New +$25.2M
TMO icon
38
Thermo Fisher Scientific
TMO
$220B
$26.5M 0.41%
50,000
-240,334
-83% -$116M
URGN icon
39
UroGen Pharma
URGN
$2.29B
$25.9M 0.4%
1,726,808
+869,344
+101% +$11.3M
RDNT icon
40
RadNet
RDNT
$5.69B
$23.1M 0.36%
+663,602
New +$20.9M
SWTX
41
DELISTED
SpringWorks Therapeutics
SWTX
$22.8M 0.36%
+625,000
New +$16.3M
STOK icon
42
Stoke Therapeutics
STOK
$2.11B
$21.7M 0.34%
4,131,045
-259,513
-6% -$1.11M
TNGX icon
43
Tango Therapeutics
TNGX
$4.41B
$19.5M 0.3%
+1,966,752
New +$17.1M
GHRS icon
44
GH Research
GHRS
$2.08B
$19.3M 0.3%
3,327,129
– –
ROIV icon
45
Roivant Sciences
ROIV
$26.2B
$16.3M 0.26%
1,454,273
-98,444
-6% -$959K
IMTX icon
46
Immatics
IMTX
$1.32B
$15.6M 0.24%
1,484,911
+639,911
+76% +$5.89M
EPIX
47
DELISTED
ESSA Pharma
EPIX
$15.2M 0.24%
+2,298,662
New +$11.3M
GH icon
48
Guardant Health
GH
$22.6B
$13.3M 0.21%
492,977
-7,910
-2% -$207K
VRDN icon
49
Viridian Therapeutics
VRDN
$2.67B
$13.2M 0.21%
+605,816
New +$9.56M
ALUR
50
DELISTED
Allurion Technologies
ALUR
$12.9M 0.2%
138,308
– –
1
2
3 4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q4 2023 Portfolio in Review

As of Q4 2023, RTW Investments held 81 positions worth $6.4B, up 35% from $4.74B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

RTW Investments deployed $453M of net new capital in Q4 2023, opening 14 new positions and adding to 12 existing holdings. Its largest new stake was Arvinas: 4,213,483 shares worth $173M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $116M trimmed.

  • RTW Investments's largest Q4 2023 buy was Arvinas: 4,213,483 shares worth $173M.
  • RTW Investments added most to Madrigal Pharmaceuticals in Q4 2023, an estimated $88.5M increase.
  • RTW Investments's biggest Q4 2023 reduction was Thermo Fisher Scientific, cutting an estimated $116M.
  • RTW Investments fully exited MoonLake Immunotherapeutics in Q4 2023, selling an estimated $28.5M.
  • RTW Investments's ten largest holdings make up 53% of its $6.4B portfolio in Q4 2023.
  • RTW Investments opened 14 new positions and closed 17 in Q4 2023.
  • RTW Investments's portfolio value rose 35% quarter-over-quarter to $6.4B.

Based on RTW Investments's 13F filing for Q4 2023, filed 14 Feb 2024.